These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15452738)

  • 1. Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first year.
    Ramsberg J; Odeberg S; Engström A; Lundin D
    Eur J Health Econ; 2004 Dec; 5(4):351-6. PubMed ID: 15452738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Quality of Economic Evaluations of FDA Novel Drug Approvals: A Systematic Review.
    Woersching AL; Borrego ME; Raisch DW
    Ann Pharmacother; 2016 Dec; 50(12):1028-1040. PubMed ID: 27489087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

  • 4. Examining the value and quality of health economic analyses: implications of utilizing the QHES.
    Ofman JJ; Sullivan SD; Neumann PJ; Chiou CF; Henning JM; Wade SW; Hay JW
    J Manag Care Pharm; 2003; 9(1):53-61. PubMed ID: 14613362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View.
    Djalalov S; Djalalova D; Krahn M; Matveev N; Hoch JS
    Value Health Reg Issues; 2019 Sep; 19():138-144. PubMed ID: 31472421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluations and diabetes.
    Pathak DS; Burke TA
    Pharm Pract Manag Q; 1998 Jan; 17(4):17-24. PubMed ID: 10174745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health economic evaluation reporting guideline and application status].
    Xiao J; Sun JF; Wang QQ; Qi X; Yao HY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Mar; 51(3):276-280. PubMed ID: 28260345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
    Brereton N; Pennington B; Ekelund M; Akehurst R
    J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What affects the quality of economic analysis for life-saving investments?
    Hahn RW; Kosec K; Neumann PJ; Wallsten S
    Risk Anal; 2006 Jun; 26(3):641-55. PubMed ID: 16834624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics--what the nephrologist should know.
    Palmer AJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1038-41. PubMed ID: 15840678
    [No Abstract]   [Full Text] [Related]  

  • 16. The costs and benefits of regulations for reimbursement of new drugs.
    Lundkvist J; Jönsson B; Rehnberg C
    Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of utility.
    Thavorncharoensap M
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S43-9. PubMed ID: 24964698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of economic evaluation guidelines: 2 years' experience in Canada.
    Baladi JF; Menon D; Otten N
    Health Econ; 1998 May; 7(3):221-7. PubMed ID: 9639335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries.
    Eljilany I; El-Dahiyat F; Curley LE; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):403-414. PubMed ID: 29779401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.